UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.3-24

2010

Volltextzugriff (PDF)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

JAMA neurology, 2022-10, Vol.79 (10), p.1015

2022

Volltextzugriff (PDF)

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1258-1267

2023

Volltextzugriff (PDF)

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Alzheimer's & dementia, 2023-06, Vol.19 (S7), p.n/a

2023

Volltextzugriff (PDF)

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Alzheimer's & dementia, 2023-06, Vol.19 (6), p.2253-2264

2023

Volltextzugriff (PDF)

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

European journal of cancer (1990), 2016-10, Vol.66, p.95-103

2016

Volltextzugriff (PDF)

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Alzheimer's & dementia, 2023-12, Vol.19 (S14), p.n/a

2023

Volltextzugriff (PDF)

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Pharmaceutical research, 2014-10, Vol.31 (10), p.2829-2843

2014

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Journal of pharmacokinetics and pharmacodynamics, 2004-06, Vol.31 (3), p.185-213

2004

Volltextzugriff (PDF)

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Xenobiotica, 2018-04, Vol.48 (4), p.382-399

2018

Volltextzugriff (PDF)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309-323

2015

Volltextzugriff (PDF)

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

Journal of pharmacokinetics and pharmacodynamics, 2012-04, Vol.39 (2), p.147-160

2012

Volltextzugriff (PDF)

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673

2017

Volltextzugriff (PDF)

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

European journal of clinical pharmacology, 2007-05, Vol.63 (5), p.485-498

2007

Volltextzugriff (PDF)

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Journal of pharmacokinetics and pharmacodynamics, 2006-10, Vol.33 (5), p.571-594

2006

Volltextzugriff (PDF)

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309

2015

Volltextzugriff (PDF)

Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis : diazepam case study

Journal of pharmacokinetics and pharmacodynamics, 2006-02, Vol.33 (1), p.1-27

2006

Volltextzugriff (PDF)

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Journal of pharmacokinetics and pharmacodynamics, 2005-12, Vol.32 (5-6), p.659-662

2005

Volltextzugriff (PDF)

Chimerism and tolerance post-in utero transplantation with embryonic stem cells

Transplantation, 2004-11, Vol.78 (9), p.1274-1282

2004

Volltextzugriff (PDF)

Uncertainty analysis of pharmacokinetic/pharmacodynamic models

Gueorguieva, Ivelina

2002

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

ThemaPharmacokinetics

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(20)
Dissertationen
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis : diazepam case study

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Chimerism and tolerance post-in utero transplantation with embryonic stem cells

Uncertainty analysis of pharmacokinetic/pharmacodynamic models

Aktive Filter

Suchergebnisse filtern